

Reference<br/>Number:<br/>From:FOIAH2324/007Date:CommercialDate:05 April 2023

Subject: The treatment of Haemophilia A

I am researching the incidence and treatment of Haemophilia A across different NHS trusts and health boards. I have already consulted the annual report published by the UKHCDO but need current information at the individual organisation-level, which is not present in the annual report. Can I therefore request you to answer the following question.

- Q1 In the last three months, how many patients have been treated by your haemophilia centre for prophylaxis or for bleeding episodes with the following products?
  - a. Factor VIII (any brand)\*
  - b. Hemlibra (standalone)
  - c. Hemlibra in combination with any Factor VIII

\*please note I am not seeking any commercially sensitive information - simply the total number of patients on any factor VIII product.

A1 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.